share_log

Wedbush Initiates Coverage On Prime Medicine With Outperform Rating, Announces Price Target of $12

Wedbush Initiates Coverage On Prime Medicine With Outperform Rating, Announces Price Target of $12

Wedbush以跑贏大盤的評級啓動對Prime Medicine的保險，宣佈目標股價爲12美元
Benzinga ·  04/03 04:24

Wedbush analyst David Nierengarten initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $12.

Wedbush分析師戴****倫加滕以跑贏大盤的評級啓動了對Prime Medicine（納斯達克股票代碼：PRME）的報道，並宣佈目標股價爲12美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論